NCT02365077 is a clinical trial in Femur Head Necrosis, sponsored by Xijing Hospital.

Who is sponsoring NCT02365077?

NCT02365077 is sponsored by Xijing Hospital.

What condition does NCT02365077 study?

NCT02365077 studies Femur Head Necrosis, Adverse Effect of Glucocorticoids and Synthetic Analogues.

Is NCT02365077 still recruiting?

NCT02365077 is currently status unknown. Last updated 11 March 2021.

Last reviewed 2021-03-11 · How we verify

NCT02365077

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

GWAS Identified Susceptibility Loci for Glucocorticoid-induced FHN in the Chinese Population

Status unknown Last updated 11 March 2021

What this trial tests

trial in Femur Head Necrosis in 2,500 participants. Status unknown.

Timeline

1 January 2015

Primary endpoint
31 December 2023

31 December 2023

Quick facts

Lead sponsor	Xijing Hospital
Status	Status unknown
Study type	OBSERVATIONAL
Enrollment	2,500
Start date	1 January 2015
Primary completion	31 December 2023
Estimated completion	31 December 2023
Sites	1 location across China

Conditions studied

Femur Head Necrosis — all drugs for Femur Head Necrosis →
Adverse Effect of Glucocorticoids and Synthetic Analogues — all drugs for Adverse Effect of Glucocorticoids and Synthetic Analogues →

Sponsor

Xijing Hospital

Who can join

Adults 18 to 60, any sex, with Femur Head Necrosis or Adverse Effect of Glucocorticoids and Synthetic Analogues. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a observation clinical trial. We are collecting the patients with glucocorticoid. They were divided into the experiment group (with femur head necrosis) and control group (without femur head necrosis).Then, we will analyse the patients' genome with genome-wide association study (GWAS). Our purpose is to find susceptibility loci for glucocorticoid-induced femur head necrosis in the Chinese population.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Femur Head Necrosis

Currently open trials in the same condition.

NCT06565910 — Bupivacaine Liposome Plus Bupivacaine or Ropivacaine for Pericapsular Nerve Group Block in Hip Arthroplasty (PENG) · Phase 4 · recruiting

Other Xijing Hospital trials

Trials by the same sponsor.

NCT07532096 — Extended Sentinel Lymph Node Biopsy With Methylene Blue Single Tracer Post-Neoadjuvant Therapy for Node-Positive Breast · NA · not yet recruiting
NCT07519018 — TIS for Drug Resistant TLE · NA · not yet recruiting
NCT07518992 — Correlation Between Preoperative Sleep and Postoperative Brain and Renal Dysfunction · not yet recruiting
NCT07466303 — Serplulimab Combined With Trastuzumab Rezetecan as Neoadjuvant Therapy for Triple-Negative Breast Cancer · Phase 2 · not yet recruiting
NCT07474142 — A Multicenter, Prospective Study on the Prognostic Value of PSMA PET in Patients With Newly Diagnosed, Treatment-naïve P · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02365077 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Xijing Hospital
Last refreshed: 11 March 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02365077.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing